Deal Details

Sygnature Acquires NuChem

---

Summary

About

Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organization (“CRO“) based in the UK with its headquarters in Nottingham and additional facilities in Alderley Park, Macclesfield and Glasgow. Sygnature Discovery partners with global pharma, biotech and NFP organizations. Founded in 2004, Sygnature has delivered over 40 novel pre-clinical and 22 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases and more.

Five Arrows Principal Investments has €23 billion of AuM with offices in Paris, London, New York, Los Angeles, San Francisco and Luxembourg. With over €9 billion of assets under management, FAPI is focused on investing in companies with highly defensible market positions; strong management teams; business models with high visibility of organic unit volume growth and strong unit economics; and multiple operational levers that can be used to unlock latent value. Sectors are limited to healthcare, data and software, and technology-enabled business services.

NuChem Sciences is a leading discovery CRO in the North American market and employs over 300 staff across centres of excellence in Montreal and Quebec City, Canada, where the company will continue to operate and drive further market expansion across North America. Founded in 2011, NuChem Sciences offers a range of standalone and integrated discovery services across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology. Additionally, the company provides protein chemistry services and offers crucial knowledge-based expertise in structural biology at the initial stages of drug discovery to global biotech and pharmaceutical companies.

---

CONTACT US TO LEARN MORE